United States
Parthenolide
Sesquiterpene lactone found in Tanacetum; TRPA1 partial agonist, NLRP3 and caspase 1 inhibitor.
| LKT-P0270-M025 | 25 mg | 76.00 USD |  |
||
| LKT-P0270-M100 | 100 mg | 184.00 USD | |
||
| LKT-P0270-M250 | 250 mg | 422.00 USD | |
||
Sesquiterpene lactone specifically inhibiting activation of NF-κB by preventing the degradation of IκB-α and IκB-β. Also inhibits activation of MAP kinase (MAPK/ERK) and generation of leukotriene B4 and thromboxane B2.
|
|
|||||||||||||||||||||||||||||||||||||||||||
Product Literature References
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide: N.M. Patel, et al.; Oncogene 19, 4159 (2000), Abstract;
Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells: H.R. Wong & I.Y. Menendez; BBRC 262, 375 (1999), Abstract;
The antiinflammatory sesquiterpene lactone parthenolide inhibits NF- kappa B by targeting the I kappa B kinase complex: S.P. Hehner, et al.; J. Immunol. 163, 5617 (1999), Abstract;
Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta: S.P. Hehner, et al.; J. Biol. Chem. 273, 1288 (1998), Abstract;
Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases: D. Hwang, et al.; BBRC 226, 810 (1996), Abstract;
Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta: R.W. Barsby, et al.; J. Pharm. Pharmacol. 44, 737 (1992), Abstract;
Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components: H. Sumner, et al.; Biochem. Pharmacol. 43, 2313 (1992), Abstract;
A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro: W.A. Groenewegen & S. Heptinstall; J. Pharm. Pharmacol. 42, 553 (1990), Abstract;
another CS2 website
©2018 Axxora, LLC.,
